Login to Your Account

$210M Deal Gives Endo Rights to Testosterone Gel Fortesta

By Catherine Hollingsworth

Thursday, August 27, 2009
With an FDA decision drawing near for testosterone gel Fortesta, Endo Pharmaceuticals Inc. has grabbed marketing rights to the hormone replacement therapy in the U.S. under a deal valued at up to $210 million with U.K.-based Prostrakan Group plc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription